New Hydrogen Nanocomplex Fights Drug-Resistant Kidney Cancer
- Authors
- Suxian Hu, Yan Zhu, Yi Duan, Liting Wang, Jian Yu, Zhihua Wu, Yourong Duan, Ying Sun
- Journal
- Materials Today Bio
- Year
- 2025
- DOI
- 10.1016/j.mtbio.2025.102450
- Study Type
- Cell Culture
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Clear Cell Renal Cell Carcinoma
- Body System
- Urinary System
TL;DR
A hydrogen-generating nanocomplex co-delivering PT2385 and siRNA against lncARSR effectively reverses sunitinib resistance in clear cell renal cell carcinoma by inhibiting angiogenesis and enhancing mitochondrial apoptosis.
Key Finding
A hydrogen-based nanocomplex combining hydrogen gas, PT2385, and genetic silencing of lncARSR showed synergistic effects in reducing tumor blood vessel formation and promoting cancer cell death in sunitinib-resistant kidney cancer cells.
Summary
Researchers created a nanoparticle (tiny engineered particle) that delivers hydrogen gas, a cancer drug called PT2385, and genetic material to block a resistance-causing gene in kidney cancer cells that no longer respond to standard treatment. In laboratory tests with cancer cells, this combination reduced the growth of new blood vessels that feed tumors and triggered cancer cell death by damaging their mitochondria (the cell's energy centers).
Practical Takeaway
This is early laboratory research in cancer cells only, not human studies. While the results are promising for potentially overcoming drug resistance in kidney cancer, much more testing is needed before any clinical application. The study does not provide evidence about hydrogen water or other hydrogen products available to consumers.
Abstract
Hydrogen therapy has emerged as a promising agent for cancer treatment. Earlier research demonstrated that hydrogen (H2) possesses anti-angiogenic effects across multiple tumor types. However, no studies have yet investigated the anti-angiogenic effects of H2 in sunitinib-resistant clear cell renal cell carcinoma (ccRCC) or elucidated the mechanism involved. Besides, both Hypoxia-inducible factor 2α (HIF-2α) and lncRNA Activated in RCC with sunitinib resistance (lncARSR) play essential roles in mediating ccRCC sunitinib resistance. Nevertheless, traditional multidrug combination strategy fails to achieve precise and effective suppression of drug-resistance related targets in conjunction with gas therapy. Therefore, we engineered a tumor-targeted nanocomplex, enabling localized H2 generation and efficient PT2385 and small interfering RNA targeting lncARSR (silncARSR) delivery to inhibit molecular targets associated with sunitinib resistance in ccRCC. Mechanistically, in situ generated hydrogen and lncARSR knockdown effectively suppresses tumor angiogenesis by downregulating vascular endothelial growth factor A(VEGFA) secretion from sunitinib-resistant cancer cells and M2-like tumor-associated macrophages (TAMs). Thus, the anti-angiogenic activity of PT2385 (HIF-2α inhibitor) was potentiated by H2 and silncARSR significantly. Moreover, the combination of H2, silncARSR and PT2385 exerts significantly potentiated efficacy in modulating apoptosis-related protein expression and ultimately enhancing cancer cell mitochondrial apoptosis. The demonstrated high therapeutic efficacy and great biocompatibility of this Hydrogen-PT2385-silncARSR nanocomplex underscore the clinical translation potential for overcoming ccRCC sunitinib resistance.